Salmeterol Market Analysis - Global Industry Size, Share, Trends and Forecast 2020 - 2027

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Forthcoming | Report ID : ARC2336

Gradual increase in number of patients suffering from chronic obstructive pulmonary disease (COPD) across the globe and increasing R&D activities by major players for drug development are major factors expected to drive the growth of global salmeterol market.

Changing lifestyle pattern and unhealthy consumption of food is various health issues. According to World Health Organization COPD was previously more common in men but the disease now affects men and women equally. In the United States, women are still 37 percent more likely to have COPD than men. In 2015, 3.2 million people died from COPD worldwide, an increase of 11.6 percent compared with 1990. During that same time period, the prevalence of COPD increased by 44.2 percent to 174.5 million individuals. Major players are focused on innovative drug development in order to control the COPD among people. They are investing high for R&D activities and in collaboration with public & government organization they are inclining towards introduction of innovative solution.

In 2020, Teva Pharmaceuticals a developer of specialty pharmaceutical products launched AirDuo® Digihaler® (fluticasone propionate and salmeterol) inhalation powder a digital maintenance inhaler for patients with asthma. This product launch is expected to help the company to enhance the customer base and increase the revenue base.

In 2020, Pharmascience Inc. a global manufacturer of generic drugs in a wide range of therapeutic categories launched a new product for asthma and COPD. pms-FLUTICASONE PROPIONATE/SALMETEROL DPI, a generic alternative to ADVAIR DISKUS™ is now available in Canada. This product launch is expected to help the company to strengthen its position in target market.

In 2020, Hikma Pharmaceuticals PLC a pharmaceutical company received FDA approval for its generic version of GlaxoSmithKline’s Advair Diskus® (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US. This is expected to help the company to enhance the business in US.

Increasing government spending on development of healthcare infrastructure in order to facilitate the R&D activities and approach towards enhancing the hospital capabilities in order to deliver the enhanced treatment are other factors expected to augment the growth of global salmeterol market. Factors such as stringent government regulations related to product approval and side-effects of medications are expected to hamper the growth of global salmeterol market. In addition, lack of developed infrastructure in developing countries for R&D activities is expected to challenge the growth of salmeterol market.

However, increasing investment for R&D activities by major players and development of safer product are factors expected to create new opportunities for players operating in the target market over the forecast period. In addition, developing regulatory scenario and increasing government spending on infrastructure development are factors expected to support the revenue transaction of target market.

Segment Analysis by Region

The market in North America is expected to account for major revenue share in the global salmeterol market due to high patient pool suffering from COPD. In addition, presence of large number of players, increasing R&D activities and introduction of innovative solutions are factors expected to support the growth of regional market.

Increasing business development activities by players in order to enhance the business presence and increase the customer base are factors expected to positively impact the target market growth.

Competitive Landscape      

The global market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Report coverage

Market

 Global Salmeterol Market

Analysis Period

 2016 – 2027

Base Year

 2019

Forecast Data

 2020 – 2027

Market Stratification

 Application, Distribution Channel, and Geography

Regional Scope

 North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Report Coverage

 Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis

Salmeterol Market Segment Analysis, 2019

The global salmeterol market is segmented into application and distribution channel. The application segment is bifurcated into Asthma, Bronchospasm, and OPD. The distribution channel segment is divided into hospital, surgical centers, and others. Among the distribution channel the hospital segment is expected to account for major revenue share in the target market due tin high government spending on development of hospitals in order to provide enhanced care to the patients.

The players profiled in the report are Lupin Limited, MidasCare, Teva Pharmaceutical Industries Ltd.,  GlaxoSmithKline plc, Intas Pharmaceuticals Ltd., NATCO Pharma Limited, INVENT FARMA HOLDING SPAIN S.L., Mylan N.V., Redwing Pharma, and Axa Parenterals Ltd.

Market Segmentation

Market By Application

Asthma

Bronchospasm

COPD

Market By Distribution Channel

Hospital

Surgical Centers

Others

Market By Region

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • Germany
  • France
  • Spain
  • Rest of Europe

Asia-Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC
  • South Africa
  • Rest of Middle East & Africa


Cart Summary


1